Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-05
2011-07-05
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S367000, C514S369000, C514S371000, C546S114000, C548S163000, C548S185000, C548S196000
Reexamination Certificate
active
07973051
ABSTRACT:
Compounds of formula (I)as well as pharmaceutically acceptable salts and esters thereof, wherein R1to R3have the significance given in claim1and which can be used in the form of pharmaceutical compositions.
REFERENCES:
patent: 2006 00313 (2006-03-01), None
patent: 0 337 819 (1989-10-01), None
patent: WO 01/57037 (2001-08-01), None
patent: WO 03/039451 (2003-05-01), None
patent: WO 2005/103022 (2005-11-01), None
patent: WO 2007/137962 (2007-12-01), None
patent: WO 2007/137962 (2007-12-01), None
Bouillon et al. J Comb Chem. 2007; 9(6). Author Manuscript, pp. 1-13.
Ettmayer et al. “Lessons Learned from Marketed and Investigational Prodrugs.” J. Med. Chem., (2004), 47(10): 2393-2404.
Stella, Valentino. “Prodrugs as therapeutics.” Expert Opin. Ther. Patents (2004), 14(3): 277-280.
Testa, Bernard. “Prodrug research: futile or fertile?” Biochemical Pharmacology, 68 (2004): 2097-2106.
Wolff et al. Burger's Medicinal Chemistry and Drug Discovery. 5th ed. vol. 1: Principles and Practice (1995). pp. 975-977.
Arzneimittel Forschung, Drug Research, ECV, vol. 8, No. 7a, Jan. 1, 1958, pp. 448-454—XP009088824.
Imtiaz Husain, M, The Indian Journal of Pharmacy, CC, CC, vol. 38, No. 2, Mar. 1, 1976, pp. 47-49, XP008036020.
Yousef, Medicinal Chemistry Research, vol. 10, No. 6, XP008020857, 2001.
Zee-Cheung, Journal of Medicinal Chemistry, 22 (1), 28-32, XP002520027, 1978.
Hof, H.,Antimicrobial Chemotherapy 14 (1) 31-9—XP002520028, 1984.
Husain, M.I. et al; Indian Drugs, (1986) 24:1 p. 21.
About Out A.A. et al, J. Drugs. Res. Egypt (1974) 6:2 p. 123.
Holland, G.F.; J. Org. Chem. (1961) 26, p. 1662.
Howbert, J.J. et al: J. Med. Chem. (1990) 33:9 p. 2393.
Hebeisen Paul
Kitas Eric A.
Minder Rudolf E.
Mohr Peter
Wessel Hans Peter
Anderson Rebecca L
Hoffman-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Otton Alicia L
LandOfFree
Aminothiazoles as FBPase inhibitors for diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminothiazoles as FBPase inhibitors for diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminothiazoles as FBPase inhibitors for diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2637641